Cationization of monoclonal antibodies: Another step towards the "Magic Bullet"?

Journal of Biological Regulators and Homeostatic Agents

Volumn 19, Issue 3-4, 2005, Pages 105-112

  Vaisitti, Tiziana ^a,b   Deaglio, S ^a   Malavasi, F ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Laboratory of Immunogenetics   (Italy)

Author keywords

Antibody engineering; Cationization; Magic bullet; Monoclonal antibody; Tumor associated antigen

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BASILIXIMAB; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CEAVAC; CETUXIMAB; DACLIZUMAB; EPRATUZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY M 195; OKT 3; ORTHOCLONE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; ZAMYL; ANTIBODY CONJUGATE; CATION; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY ENGINEERING; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; BREAST CANCER; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG PENETRATION; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMISTRY; IMMUNOLOGY; NEOPLASM; PROTEIN ENGINEERING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CATIONS; CLINICAL TRIALS; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; PROTEIN ENGINEERING; RADIOPHARMACEUTICALS;

EID: 33744534309     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
2. Brodsky FM. Monoclonal antibodies as magic bullets. Pharm Res 1988; 5: 1-9.
3. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003; 9: 129-34.
4. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002; 13: 603-8.
5. Kettleborough CA, Saldanha J, Heath VJ, Morrison CJ, Bendig MM. Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation. Protein Eng 1991; 4: 773-83.
6. Liu HL, Parkes DL, Langton BC, et al. Construction of a chimeric antibody with therapeutic potential for cancers which overexpress c-erbB-2. Biochem Biophys Res Commun 1995; 211: 792-803.
7. Dillman RO. The history and rationale for monoclonal antibodies in the treatment of hematologic malignancy. Curr Pharm Biotechnol 2001; 2: 293-300.
8. Ezzell C. Magic bullets fly again. Sci Am 2001; 285: 34-41.
9. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29.
10. Hudson PJ, Souriau C. Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 2001; 1: 845-55.
11. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002; 13: 609-14.
12. Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Semin Oncol 2002; 29: 105-12.
13. Leyland-Jones B. Trastuzumab: Hopes and realities. Lancet Oncol 2002; 3: 137-44.
14. Ferrajoli A, O'Brien S, Keating MJ. Alemtuzumab: A novel monoclonal antibody. Expert Opin Biol Ther 2001; 1: 1059-65.
15. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355: 735-40.
16. Hudson PJ. Recombinant antibodies: A novel approach to cancer diagnosis and therapy. Expert Opin Investig Drugs 2000; 9: 1231-42.
17. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-5.
18. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: A binding-site barrier. J Nucl Med 1990; 31: 1191-8.
19. Hoogenboom HR, Chames P. Natural and designer binding sites made by phage display technology. Immunol Today 2000; 21: 371-8.
20. Little M, Kipriyanov SM, Le Gall F, Moldenhauer G. Of mice and men: Hybridoma and recombinant antibodies. Immunol Today 2000; 21: 364-70.
21. Jager D, Taverna C, Zippelius A, Knuth A. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol Immunother 2004; 53: 144-7.
22. Pollock JD. Gene expression profiling: Methodological challenges, results, and prospects for addiction research. Chem Phys Lipids 2002; 121: 241-56.
23. Ye SQ, Usher DC, Zhang, LQ. Gene expression profiling of human diseases by serial analysis of gene expression. J Biomed Sci 2002; 9: 384-94.
24. Amatschek S, Koenig U, Auer H, et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004; 64: 844-56.
25. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9: 931-46.
26. Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 2003; 22: 1568-79.
27. Tammen H, Kreipe H, Hess R, et al. Expression profiling of breast cancer cells by differential peptide display. Breast Cancer Res Treat 2003; 79: 83-93.
28. Michener CM, Ardekani AM, Petricoin EF, 3rd, Liotta, LA, Kohn EC. Genomics and proteomics: Application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 2002; 26: 249-55.
29. Hof D, Cheung K, Roossien HE, Pruijn GJ, Raats JM. A novel subtractive antibody phage display method to discover disease markers. Mol Cell Proteomics 2005; (Epub ahead of print).
30. Kretzschmar T, von Ruden T. Antibody discovery: Phage display. Curr Opin Biotechnol 2002; 13: 598-602.
31. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002; 8: 17-23.
32. Janmaat ML, Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2003; 8: 576-86.
33. Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532: 253-68.
34. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3-11.
35. Arteaga C. Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol 2003; 30: 3-14.
36. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. Cancer Immunol Immunother 2003; 52: 328-37.
37. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003; 98: 2095-104.
38. Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol 1999; 11: 570-8.
39. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell 2003; 3: 207-12.
40. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-49.
41. Czuczman MS. Immunochemotherapy in indolent non-Hodgkin's lymphoma. Semin Oncol 2002; 29: 11-7.
42. Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study. Ann Oncol 2004; 15: 511-6.
43. Burris H, 3rd, Yardley D, Jones S, et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22: 1621-9.
44. Onda M, Wang QC, Guo HF, Cheung NK, Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004; 64: 1419-24.
45. Filipovich AH, Vallera DA, Youle RJ, et al. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation 1987; 44: 62-9.
46. Smallshaw JE, Ghetie V, Rizo J, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 2003; 21: 387-91.
47. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312: 643-6.
48. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-5.
49. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522-5.
50. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7.
51. Verhoeyen M, Riechmann L. Engineering of antibodies. Bioessays 1988; 8: 74-8.
52. Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15: 637-40.
53. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: Implications for therapeutic antibodies. Int Immunol 2001; 13: 1551-9.
54. Colcher D, Goel A, Pavlinkova G, Beresford G, Booth B, Batra SK. Effects of genetic engineering on the pharmacokinetics of antibodies. Q J Nucl Med 1999; 43: 132-9.
55. Goel A, Baranowska-Kortylewicz J, Hinrichs SH, et al. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: Novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 2001; 42: 1519-27.
56. Onda M, Nagata S, Tsutsumi Y, et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res 2001; 61: 5070-7.
57. Tomlinson I, Holliger P. Methods for generating multivalent and bispecific antibody fragments. Methods Enzymol 2000; 326: 461-79.
58. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 2001; 248: 47-66.
59. Hudson PJ, Kortt AA. High avidity scFv multimers; diabodies and triabodies. J Immunol Methods 1999; 231: 177-89.
60. Goel A, Colcher D, Baranowska-Kortylewicz J, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application. Cancer Res 2000; 60: 6964-71.
61. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999; 11: 558-62.
62. Gauthier VJ, Mannik M, Striker GE. Effect of cationized antibodies in performed immune complexes on deposition and persistence in renal glomeruli. J Exp Med 1982; 156: 766-77.
63. Triguero D, Buciak JL, Pardridge WM. Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate. J Pharmacol Exp Ther 1991; 258: 186-92.
64. Pardridge WM, Bickel U, Buciak J, Yang J, Diagne A, Aepinus C. Cationization of a monoclonal antibody to the human immunodeficiency virus REV protein enhances cellular uptake but does not impair antigen binding of the antibody. Immunol Lett 1994; 42: 191-5.
65. Pardridge WM, Kang YS, Yang J, Buciak JL. Enhanced cellular uptake and in vivo biodistribution of a monoclonal antibody following cationization. J Pharm Sci 1995; 84: 943-8.
66. Devenny JJ, Wagner RC. Transport of immunoglobulin G by endothelial vesicles in isolated capillaries. Microcirc Endothelium Lymphatics 1985; 2: 15-26.
67. Apple RJ, Domen PL, Muckerheide A, Michael JG. Cationization of protein antigens. IV. Increased antigen uptake by antigen-presenting cells. J Immunol 1988; 140: 3290-5.
68. Triguero D, Buciak JB, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G: Enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989; 86: 4761-5.
69. Rosebrough SF, Hartley DF. Biochemical modification of streptavidin and avidin: In vitro and in vivo analysis. J Nucl Med 1996; 37: 1380-4.
70. Yao Z, Zhang M, Sakahara H, et al. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment. Nucl Med Biol 1998; 25: 557-60.
71. Pardridge WM, Buciak J, Yang J, Wu D. Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein. J Pharmacol Exp Ther 1998; 286: 548-54.
72. Lee HJ, Pardridge WM. Monoclonal antibody radiopharmaceuticals: Cationization, pegylation, radiometal chelation, pharmacokinetics, and tumor imaging. Bioconjug Chem 2003; 14: 546-53.
73. Bickel U, Lee VM, Trojanowski JQ, Pardridge WM. Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: A potential probe for Alzheimer's disease. Bioconjug Chem 1994; 5: 119-25.
74. Hong G, Bazin-Redureau MI, Scherrmann JM. Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. J Pharm Sci 1999; 88: 147-53.
75. Hong G, Chappey O, Niel E, Scherrmann JM. Enhanced cellular uptake and transport of polyclonal immunoglobulin G and fab after their cationization. J Drug Target 2000; 8: 67-77.
76. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug Chem 1999; 10: 502-11.
77. Muckerheide A, Apple RJ, Pesce AJ, Michael JG. Cationization of protein antigens. I. Alteration of immunogenic properties. J Immunol 1987; 138: 833-7.
78. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys 1993; 20: 551-67.